CD274 and triple-negative breast carcinoma: In 2020, Zhang’s group developed a new PD-L1 aptamer–PTX conjugate that enhanced the anti-proliferative efficacy in PD-L1-overexpressing triple-negative breast cancer cells (Wu et al., 2020).